5Cannabis and Hallucinogens
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pioneering the Future of Global Cannabis June 2020
Pioneering the Future of Global Cannabis June 2020 ©2020 TILRAY Disclaimer Investors and prospective investors should rely only on the information contained in the continuous expected; that adverse changes or developments affecting the Company’s main or planned facilities may Although management has attempted to identify important risk factors that could cause actual results to disclosure filings (the “Filings”) of Tilray Inc. (the “Company”). This presentation is qualified in its entirety have an adverse effect on the Company; that the medical cannabis industry and market may not continue differ materially from those contained in the forward-looking information in this presentation, there may by reference to, and must be read in conjunction with, the information contained in the Filings. An investor to exist or develop as anticipated or the Company may not be able to succeed in this market; that the be other risk factors not presently known to the Company or that the Company presently believes are not or prospective investor is not entitled to rely on parts of the information contained in this presentation to Company has a limited operating history and a history of net losses and that it may not achieve or maintain material that could also cause actual results or future events to differ materially from those expressed in the exclusion of others, and the Company is not authorized to provide different or additional information. profitability in the future; risks related to the Company’s current or proposed international operations; risks such forward-looking information in this presentation. There can be no assurance that such information Unless otherwise specified, all monetary amounts in this presentation are in United States dollars. -
International Narcotics Control Strategy Report
United States Department of State Bureau for International Narcotics and Law Enforcement Affairs International Narcotics Control Strategy Report Volume I Drug and Chemical Control March 2017 INCSR 2017 Volume 1 Table of Contents Table of Contents Common Abbreviations ............................................................................................................................. iii International Agreements .......................................................................................................................... v INTRODUCTION ........................................................................................................................................... 1 Policy and Program Developments ......................................................................................................... 17 Overview ................................................................................................................................................. 18 Methodology for U.S. Government Estimates of Illegal Drug Production ............................................... 24 (with dates ratified/acceded) ................................................................................................................... 30 USG Assistance ..................................................................................................................................... 36 International Training ............................................................................................................................. -
In Focus Cannabis Legalization 4
IN FOCUS CANNABIS LEGALIZATION 4 2020 Developments in jurisdictions with measures regulating the non-medical use of cannabis of cannabis products for medical purposes had DEVELOPMENTS IN already been allowed in Canada as early as 1999. JURISDICTIONS WITH The objectives of the current cannabis legislation in MEASURES REGULATING Canada are to keep cannabis away from young people (under 18 years of age), to prevent criminals THE NON-MEDICAL USE from profiting from the distribution and sale of can- OF CANNABIS nabis and to safeguard public health and safety by allowing adults (aged 18 and older) legal access to As at December 2019, legal provisions had been cannabis.322 Under the constitutional division of approved in Canada, Uruguay and in 11 jurisdic- powers in Canada, the federal Government and pro- tions in the United States, including the District of vincial governments have different responsibilities.323 Columbia and the Northern Mariana Islands, to As the provinces historically developed their own allow the production and sale of cannabis products systems to regulate the sale of alcohol, a similar for non-medical use. The common feature of the approach has been applied to regulate the non-med- legislation in Canada and in the jurisdictions in the ical use of cannabis products. United States is that most of them allow for-profit To monitor the outcome of the new cannabis reg- industry to produce and sell cannabis products for ulations, the Government of Canada has invested non-medical use. There are some differences in the in a formal system that may eventually help to eval- level of regulation, its implementation and the con- uate their impact and support the further trol of the non-medical use of cannabis (see tables development of policies and programmes. -
Accepted Manuscript
Accepted Manuscript Title: Growing medicine: Small-scale cannabis cultivation for medical purposes in six different countries Author: Pekka Hakkarainen Vibeke Asmussen Frank Monica J. Barratt Helle Vibeke Dahl Tom Decorte Karoliina Karjalainen Simon Lenton Gary Potter Bernd Werse PII: S0955-3959(14)00173-X DOI: http://dx.doi.org/doi:10.1016/j.drugpo.2014.07.005 Reference: DRUPOL 1418 To appear in: International Journal of Drug Policy Received date: 18-4-2014 Revised date: 4-7-2014 Accepted date: 7-7-2014 Please cite this article as: Hakkarainen, P., Frank, V. A., Barratt, M. J., Dahl, H. V., Decorte, T., Karjalainen, K., Lenton, S., Potter, G., and Werse, B.,Growing medicine: Small-scale cannabis cultivation for medical purposes in six different countries, International Journal of Drug Policy (2014), http://dx.doi.org/10.1016/j.drugpo.2014.07.005 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Growing medicine: Small-scale cannabis cultivation for medical purposes in six different countries Pekka Hakkarainen1, Vibeke Asmussen Frank2, Monica J. Barratt3,6, Helle Vibeke Dahl2, Tom Decorte4, Karoliina Karjalainen5, Simon Lenton6, Gary Potter7 & Bernd Werse8 1 Corresponding author, Department of Alcohol, Drugs and Addiction, National Institute for Health and Welfare (THL), P.O. -
The Burgeoning Recognition and Accommodation of The
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Ghent University Academic Bibliography International Journal of Drug Policy 58 (2018) 93–103 Contents lists available at ScienceDirect International Journal of Drug Policy journal homepage: www.elsevier.com/locate/drugpo Policy Analysis The burgeoning recognition and accommodation of the social supply of T drugs in international criminal justice systems: An eleven-nation comparative overview ⁎ Ross Coombera, , Leah Moyleb, Vendula Belackovac, Tom Decorted, Pekka Hakkarainene, Andrew Hathawayf, Karen Joe Laidlerg, Simon Lentonh, Sheigla Murphyi, John Scottj, Michaela Stefunkovak, Katinka van de Venl, Marieke Vlaemynckd, Bernd Wersem a Department of Sociology, Social Policy and Criminology, University of Liverpool, Eleanor Rathbone Building, Bedford Street South, L69 7ZA, United Kingdom b Griffith Criminology Institute, Griffith University, Gold Coast Campus G06_2.08, Queensland, 4222, Australia c Department of Insitutional Economics, University of Economics, UE Prague, W. Churchill Sq. 4, 130 67 Prague 3, Czech Republic d Institute for Social Drug Research (ISD), Ghent University, Universiteitstraat 4, 9000, Ghent, Belgium e Alcohol, Drug and Addictions Unit, National Institute for Health and Welfare, PO Box 30, FI-00271, Helsinki, Finland f Department of Sociology and Anthropology, University of Guelph, Guelph, Ontario, N1G 2W1, Canada g Department of Sociology, University of Hong Kong, The Jockey Club Tower, Centennial Campus, Pokfulam Road, Hong Kong, China h National Drug Research Institute, Curtin University, Building 609, Level 2, 7 Parker Place Technology Park, Bentley, WA, 6102, Australia i Center for Substance Abuse Studies, Institute for Scientific Analysis, 390 4th Street, Second Floor, San Francisco, CA, 94107, USA j School of Justice, Faculty of Law, Queensland University of Technology, Level 4, C Block, Gardens Point, 2 George St, Brisbane, QLD, 4000, Australia k Institute of Criminology and Social Prevention, Namesti 14. -
Legalisation in South America
Interest in medical cannabis is growing worldwide, resulting in many countries legalising cannabis for medical use. In particular, the South American market is progressing rapidly and has become a focus for biotech companies seeking to gain a foothold in the global medicinal cannabis market. Consumer perceptions are shifting, with recent studies showing 70% of South Americans agree with the use of medical cannabis and 51% are in favour of legalising cannabis9. However, legislation is still catching up as only six countries in South America have legalised cannabis for medical or recreational use – these are: Argentina, Brazil, Chile, Colombia, Paraguay and Uruguay1. LEGALISATION IN SOUTH AMERICA Argentina – as of March 2017, Argentina has legalised cannabis oil for the treatment of serious medical conditions2. This new law permits the cultivation of cannabis for distribution and research2. The Argentinean government also provides a medical cannabis research program that guarantees free access to cannabis oil to patients who join the program12. Brazil - has the largest population of any country in South America and has partially legalised cannabis use11. To date, the government has decriminalised the possession of small amounts of cannabis1. However, support for cannabis use is growing as in March 2017, the health department of Brazil approved the country’s first-ever license to sell a cannabis-based medical product, Mevatyl (also known as Sativex)3 which is a mouth spray for multiple sclerosis patients2. Colombia - has legalised cannabis for medical use1. This move was made in the hope of diminishing Colombia’s drug trafficking business13. As part of its peace process with the Revolutionary Armed Forces of Colombia (FARC), Colombia also plans to offer a crop substitution program for farmers of illegal coca crops to cultivate cannabis legally instead1. -
Commission on Narcotic Drugs Report of the Sixteenth Session (24 April - 10 May 1961)
E/35U / E/CN.7/411 · __n~~VANCE UN UBRARY NOV 1 ;j )~bl UN/SA COLLECl\ON UNITED NATIONS COMMISSION ON NARCOTIC DRUGS REPORT OF THE SIXTEENTH SESSION (24 APRIL - 10 MAY 1961) ECONOMIC AND SOCIAL COUNCIL OFFICIAL RECORDS: THffiTY-SECOND SESSION J SUPPLEMENT No. 9 GENEVA CONTENTS Chapter Paragraphs Page I. Organizational and administrative matters. .. .. .. .. .. .. .. .. 1-20 Representation at the session. 1-11 Opening and duration of the session . .. .. .. .. .. ... ........ ... 12 2 Election of officers ... ............. ..... ... ..... .. .......... ... 13 2 Adoption of the agenda ....... ......... ....... ... .......... ... ..... 14-15 2 Report of the Commission to the Economic and Social Council on its sixteenth session. .... ...... .. ... ......... ....... ... .... .. ........... .. .. 16 3 Organization of the seventeenth session of the Commission ............. ... .. 17-19 3 Place of meeting of the seventeenth session of the Commission..... .......... 20 3 II. Implementation of the treaties and international control ....... ................. 21-70 4 Report of the Division of Narcotic Drugs ...... .. .. ...... .......... .. ... 21-23 4 List of drugs under international control. ...... .. ... .. ............ ....... 24-27 4 Ratifications, acceptance, accessions and declarations concerning the multilateral treaties on narcotic drugs . .... .. .................. .. ........... .... 28-31 4 Annual reports of governments made in pursuance of article 21 of the 1931 Convention . .. .. .. .... .. .. .. ...... .. .... .... .. .... ...... -
2020 International Narcotics Control Strategy Report
United States Department of State Bureau for International Narcotics and Law Enforcement Affairs International Narcotics Control Strategy Report Volume I Drug and Chemical Control March 2020 INCSR 2020 Volume 1 Table of Contents Table of Contents Common Abbreviations ..................................................................................................................................... iii International Agreements.................................................................................................................................... v INTRODUCTION ..................................................................................................................................... 1 Legislative Basis for the INCSR ......................................................................................................................... 2 Presidential Determination ................................................................................................................................. 7 Policy and Program Developments .................................................................................................... 12 Overview ......................................................................................................................................................... 13 Methodology for U.S. Government Estimates of Illegal Drug Production .......................................................... 18 Parties to UN Conventions .............................................................................................................................. -
Khiron Life Sciences
12th July 2019 BUY KHIRON LIFE Fair Value CAD4 SCIENCES Share price EUR1.90 Bloomberg / Reuters KHRN CN/KHRN.V Consumer, Brands & Retail Cannabis Bold Ambition Khiron is set up to be a leader in the Latin American medicinal and branded CPG cannabis markets. From its base in Colombia it is spreading out into Mexico, Peru, Chile, Uruguay and Brazil. Supported by a strong team of seasoned entrepreneurs (and a knowledgeable Board that includes former President of Mexico, Vicente Fox), the company is aiming to take a first mover advantage in the medicinal cannabis and CBD- based branded Consumer packaged goods. We initiate the stock with Buy and a fair value of CAD4.0 per share offering a 100% upside. Its position in medically-validated cannabis products is most advanced in Colombia where the company is fully licensed for the cultivation, production, domestic distribution, and international export of both THC and CBD medical cannabis. It is currently preparing the market for its medicinal cannabis products (to be launched in H2 2019) through in-person clinic consultations, medical association alliances, alliances with pharmacies, health insurance and providing physicians with a variety of cannabis education platforms. In order to accelerate the market development and its own market position, the company has already bought the ILANS clinics in Colombia but we expect more to come. The advantage of running its own neuropathic clinic is that it is much easier to educate doctors in the uses of medicinal cannabis and to switch patients towards the use of medicinal cannabis. Meanwhile, the company’s own developed CBD ski- care brand Kuida is leading the efforts in the health & wellness category. -
Universidade Federal Do Rio Grande Do Sul Faculdade
UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL FACULDADE DE AGRONOMIA PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIA DO SOLO MÉTODOS APLICADOS À RASTREABILIDADE DE Cannabis sativa L. (MACONHA) EM TERRITÓRIO BRASILEIRO Mauro Sander Fett (Tese) UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL FACULDADE DE AGRONOMIA PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIA DO SOLO MÉTODOS APLICADOS À RASTREABILIDADE DE Cannabis sativa L. (MACONHA) EM TERRITÓRIO BRASILEIRO MAURO SANDER FETT Engenheiro Agrônomo (UFRGS) Mestre em Economia Rural (UFRGS) Tese apresentada como um dos requisitos à obtenção do Grau de Doutor em Ciência do Solo Orientador: Prof. Dr. Flávio Anastácio de Oliveira Camargo Porto Alegre (RS) Outubro de 2017 CIP - Catalogação na Publicação Fett, Mauro Sander MÉTODOS APLICADOS A RASTREABILIDADE DE Cannabis sat iva L . (MACONHA ) EM TERRITÓRI O BRASILEIRO I Mauro Sander Fett. -- 2017. 97 f. Ori entador : Flávi o Anastácio de Oli veira Camargo . Tese (Do utorado) -- Universidade Federal do Rio Grande do Sul, Facul dade de Agronomia, Programa de Pós- Graduação em Ciência do Solo, Porto Alegre, BR- RS, 2017 . 1 . Rastreabilidade. 2 . Cannabi s sativa L . 3. Ci ência forense . 4 . Composição química. 5 . Marcadores genéticos . I. Camargo, Flávio Anastácio de Oliveira, orient . II . Título . Elaborada pelo Sistema de Geração Automática de Ficha Catalogrâfica da UFRGS com os dados fornecidos pelo(a) autor(a ). Dedico à minha família, especialmente meu pai e minha mãe. ii AGRADECIMENTOS Ao professor Flávio Camargo pela orientação e amizade no período do doutorado. Aos colegas de trabalho Rafael Ortiz e Eduardo Ávila pelo incentivo e contribuições no trabalho. Aos pesquisadores, amigos e colaboradores deste projeto de estudo, Gleidson Gimenes, Roberta Mariot e Leonardo Capeleto pelo apoio nos trabalhos. -
CANNABIS in LATIN AMERICA: the Regulations and Opportunities
CANNABIS IN LATIN AMERICA: The Regulations and Opportunities © 2019 Anne Holland Ventures Inc. All Rights Reserved RE S GIS N T IG E S R E E D D C Y O T I M N M U Cannabis in Latin America: The Regulations and Opportunities MJBIZDAILY.COM/INTL CANNABIS IN LATIN AMERICA: THE REGULATIONS AND OPPORTUNITIES The marijuana industry continues to expand internationally, with Latin America and the Caribbean becoming increasingly more difficult to ignore for companies with global aspirations. The geographical region that stretches from the southern border of the United States until the southern tip of South America, including the Caribbean, is home to about 650 million people, of which the vast majority live in a country with some sort of legal medical cannabis. The sheer number of inhabitants, ideal growing conditions in large parts of the region and jurisdictions in favor of production for export signal potentially huge business opportunities. With this report, our goal is to provide a sober analysis, recognizing the prospects that the region as a whole and each country in particular offer. But we also pay close attention to Alfredo Pascual the other side of the coin: weighing the unique challenges of investing or doing business in these jurisdictions. Whenever world maps are colored to show the countries that have some form of legal medical cannabis framework, Latin America is included almost in its entirety. But, as is often the case, the devil is in the details. Restrictive access schemes, lack of health insurance coverage and widespread home growing moderate any initial excitement about the commercial opportunities in these markets. -
Alcohol, Cannabis and Impaired Driving
ALCOHOL, CANNABIS AND IMPAIRED DRIVING July 11, 2018 R. Solomon, Distinguished University Professor, Faculty of Law, Western University; K. Mahdi, J.D. 2020, Faculty of Law, Western University; & A. Sohrevardi, J.D. 2020, Faculty of Law, Western University TABLE OF CONTENTS 2 INTRODUCTION .................................................................................................. 5 ALCOHOL ............................................................................................................... 7 PART I: ALCOHOL CONSUMPTION .......................................................................... 7 Section 1: Global ................................................................................................................. 7 Section 2: Alcohol Consumption in Canada .................................................................... 8 (a) Background Information ......................................................................................... 8 (b) Rates and Patterns of Alcohol Consumption ......................................................... 10 PART II: IMPAIRED DRIVING IN CANADA ............................................................... 15 Section 1: Rates of Driving After Alcohol Consumption ................................................ 15 Section 2: Impaired Driving Crashes ............................................................................... 17 (a) A Note on the Impaired Driving Crash Data ......................................................... 17 (b) Alcohol-Related Crash Deaths and